# Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

> **NCT00367783** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 100 (—)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** CP-741,952

## Key facts

- **NCT ID:** NCT00367783
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 100 (—)
- **Why stopped:** See Detailed Description for termination reason.
- **Last updated:** 2011-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00367783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00367783, "Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00367783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*